Notice Concerning Revisions to Financial Results Forecast
Filed with TSE · · 2 pages · English
Summary by 6ix AI
The company expects an increase in net sales and operating profit due to better-than-expected performance in several product lines, despite a projected decline in profit attributable to owners of the parent. The revised forecast will be detailed alongside the consolidated financial results announcement scheduled for early November.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Kissei Pharmaceutical Co., Ltd. on 6ix
Earlier from Kissei Pharmaceutical
- Announcement for the Results Report by the Council of Pharmaceutical Affairs (Mdical Product Second Section) on TAVNEOS
- Notice Concerning Status of Acquisition of Treasury Shares
- Notice of Completion of Payment for Treasury Shares Disposal as Restricted Stock for Employee Shareholding Association and Partial
- Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
- Notice Regarding Completion of Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
Later from Kissei Pharmaceutical
- Consolidated Financial Results for the Six Months Ended September 30, 2026 [Japanese GAAP]
- Notice Concerning the Purchase of Treasury Shares through ToSTNeT-3
- Supplementary Explanatory Materials on Financial Results for the Six Months Ended September 30, 2026
- Notice Concerning the Results of the Acquisition of Treasury Shares through ToSTNeT-3
- Financial Briefing for the Second Quarter (Interim) of the Fiscal Year Ended March 31, 2027 (Fiscal 2026)
Follow Kissei Pharmaceutical into a list and get an email when it puts out news.
Follow Kissei Pharmaceutical